| Segment Reporting |
Information regarding our segments is presented in the following tables. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2026 | | (in millions) | | Healthcare | | AST | | Life Sciences | | Corporate | | Company | | | | | | | | | | | | | Revenues | | $ | 4,208.6 | | | $ | 1,138.5 | | | $ | 588.8 | | | $ | — | | | $ | 5,935.9 | | | | | | | | | | | | | | Segment expenses | | | | | | | | | | | | Cost of revenues | | 2,422.5 | | | 552.8 | | | 262.7 | | | | | | | Selling, general, and administrative | | 652.3 | | | 57.7 | | | 65.0 | | | | | | | Research and development | | 97.5 | | | 3.3 | | | 10.3 | | | | | | | Total income from operations before adjustments | | $ | 1,036.4 | | | $ | 524.7 | | | $ | 251.0 | | | $ | (430.1) | | | $ | 1,381.9 | | | Less: Adjustments | | | | | | | | | | | Amortization of acquired intangible assets (1) | | | | | | | | | | 265.0 | | Acquisition and integration related charges (2) | | | | | | | | | | 6.2 | | Tax restructuring costs (3) | | | | | | | | | | 0.5 | | Amortization of inventory and property "step up" to fair value (1) | | | | | | | | | | 5.0 | | Restructuring charges (4) | | | | | | | | | | 3.4 | | Total income from operations | | | | | | | | | | $ | 1,101.8 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2025 | | (in millions) | | Healthcare | | AST | | Life Sciences | | Corporate | | Company | | | | | | | | | | | | | Revenues | | $ | 3,878.7 | | | $ | 1,038.6 | | | $ | 542.3 | | | $ | — | | | $ | 5,459.5 | | | | | | | | | | | | | | Segment expenses | | | | | | | | | | | | Cost of revenues | | 2,204.1 | | | 516.7 | | | 243.7 | | | | | | | Selling, general, and administrative | | 610.0 | | | 52.5 | | | 59.8 | | | | | | | Research and development | | 93.1 | | | 3.8 | | | 9.4 | | | | | | | Total income from operations before adjustments | | $ | 971.5 | | | $ | 465.6 | | | $ | 229.4 | | | $ | (399.0) | | | $ | 1,267.5 | | | Less: Adjustments | | | | | | | | | | | Amortization of acquired intangible assets (1) | | | | | | | | | | 273.8 | | Acquisition and integration related charges (2) | | | | | | | | | | 11.2 | | Tax restructuring costs (3) | | | | | | | | | | 0.1 | | Amortization of inventory and property "step up" to fair value (1) | | | | | | | | | | 5.4 | | Restructuring charges (4) | | | | | | | | | | 62.3 | | Illinois EO litigation settlement (5) | | | | | | | | | | 48.2 | | Total income from operations | | | | | | | | | | $ | 866.6 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2024 | | (in millions) | | Healthcare | | AST | | Life Sciences | | Corporate | | Company | | | | | | | | | | | | | Revenues | | $ | 3,613.0 | | | $ | 954.0 | | | $ | 571.7 | | | $ | — | | | $ | 5,138.7 | | | | | | | | | | | | | | Segment expenses | | | | | | | | | | | | Cost of revenues | | 2,083.9 | | | 458.4 | | | 283.9 | | | | | | | Selling, general, and administrative | | 568.0 | | | 51.7 | | | 58.2 | | | | | | | Research and development | | 89.8 | | | 4.1 | | | 8.3 | | | | | | | Total income from operations before adjustments | | $ | 871.4 | | | $ | 439.7 | | | $ | 221.3 | | | $ | (348.5) | | | $ | 1,184.0 | | | Less: Adjustments | | | | | | | | | | | Amortization of acquired intangible assets (1) | | | | | | | | | | 266.4 | | Acquisition and integration related charges (2) | | | | | | | | | | 25.5 | | Tax restructuring costs (3) | | | | | | | | | | 0.6 | | Net loss on divestiture of businesses (1) | | | | | | | | | | 0.9 | | Amortization of inventory and property "step up" to fair value (1) | | | | | | | | | | 10.0 | | Restructuring charges (4) | | | | | | | | | | 44.4 | | Total income from operations | | | | | | | | | | $ | 836.1 | |
(1) For more information regarding our recent acquisitions and divestitures, refer to Note 3 titled, "Business Acquisitions, Divestitures, and Investments" (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring". (5) For more information regarding our Illinois EO litigation settlement, refer to Note 12 titled, "Commitments and Contingencies". | | | | | | | | | | | | | | | | (in millions) | | | | | | March 31, | | 2026 | | 2025 | | Assets | | | | | | Healthcare and Life Sciences | | $ | 7,146.8 | | | $ | 6,806.4 | | | AST | | 3,590.4 | | | 3,340.4 | | | Total assets | | $ | 10,737.2 | | | $ | 10,146.8 | |
| | | | | | | | | | | | | | | | | | | | | | Years Ended March 31, | | 2026 | | 2025 | | 2024 | | Capital Expenditures | | | | | | | | Healthcare and Life Sciences | | $ | 130.6 | | | $ | 142.8 | | | $ | 114.2 | | | AST | | 238.4 | | | 227.2 | | | 237.0 | | | Total Capital Expenditures | | $ | 369.0 | | | $ | 370.1 | | | $ | 351.2 | | | Depreciation, Depletion, and Amortization | | | | | | | | Healthcare and Life Sciences | | $ | 329.8 | | | $ | 334.2 | | | $ | 322.2 | | | AST | | 156.8 | | | 142.0 | | | 127.8 | | | Total Depreciation, Depletion, and Amortization | | $ | 486.5 | | | $ | 476.2 | | | $ | 450.1 | |
|
| Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
| | | | | | | | | | | | | | | | (in millions) | | | | | | March 31, | | 2026 | | 2025 | | Property, Plant, and Equipment, Net | | | | | | Ireland | | $ | 88.1 | | | $ | 74.9 | | | United States | | 1,094.4 | | | 1,008.7 | | | Other locations | | 978.7 | | | 872.9 | | | Property, Plant, and Equipment, Net | | $ | 2,161.2 | | | $ | 1,956.5 | |
| | | | | | | | | | | | | | | | | | | | | | (in millions) | | | | | | | | Years Ended March 31, | | 2026 | | 2025 | | 2024 | | Revenues: | | | | | | | | Ireland | | $ | 108.5 | | | $ | 107.3 | | | $ | 82.7 | | | United States | | 4,333.8 | | | 4,007.6 | | | 3,751.4 | | | Other locations | | 1,493.7 | | | 1,344.6 | | | 1,304.6 | | | Total Revenues | | $ | 5,935.9 | | | $ | 5,459.5 | | | $ | 5,138.7 | |
|
| Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue |
| | | | | | | | | | | | | | | | | | | | | | (in millions) | | | | | | | | Years Ended March 31, | | 2026 | | 2025 | | 2024 | | Healthcare: | | | | | | | | Capital equipment | | $ | 1,095.9 | | | $ | 1,037.2 | | | $ | 1,091.5 | | | Consumables | | 1,496.6 | | | 1,396.0 | | | 1,248.4 | | | Service | | 1,616.0 | | | 1,445.4 | | | 1,273.1 | | | Total Healthcare Revenues | | $ | 4,208.6 | | | $ | 3,878.7 | | | $ | 3,613.0 | | | AST: | | | | | | | | Capital equipment | | $ | 20.0 | | | $ | 30.9 | | | $ | 14.5 | | | Service | | 1,118.5 | | | 1,007.6 | | | 939.5 | | | Total AST Revenues | | $ | 1,138.5 | | | $ | 1,038.6 | | | $ | 954.0 | | | Life Sciences: | | | | | | | | Capital equipment | | $ | 135.7 | | | $ | 117.5 | | | $ | 155.5 | | | Consumables | | 308.3 | | | 286.7 | | | 251.6 | | | Service | | 144.8 | | | 138.1 | | | 164.6 | | | Total Life Sciences Revenues | | $ | 588.8 | | | 542.3 | | | 571.7 | | | Total Revenues | | $ | 5,935.9 | | | $ | 5,459.5 | | | $ | 5,138.7 | |
|